Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab, Rituximab and Radiation Bridging in LBCL
NCT05929716Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
A Phase 2 trial of magrolimab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2023; status: withdrawn.
02
Drugs
magrolimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05929716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929716.